Sinntaxis has an established discovery platform for preclinical studies of stroke recovery, and has filed IP on the use of negative allosteric modulators of the metabotropic glutamate receptor 5 for the treatment of stroke recovery.
Sinntaxis
Is committed to discovering, developing and commercialising novel therapeutics that enhance recovery of brain functions after stroke.